TruScreen Group Limited, together with its subsidiaries, develops, manufacture, and sale of cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, Eastern Europe, the Middle East/North Africa, and internationally. The company offers the TruScreen cervical cancer screening device, a medical device for identifying and detecting the presence of precancerous and cancerous tissue on the cervix in real time. The company was formerly known as TruScreen Limited and changed its name to Truscreen Group Limited in August 2020. TruScreen Group Limited was incorporated in 2013 and is headquartered in Auckland, New Zealand.
Metrics to compare | TRU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTRUPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.8x | −2.6x | −0.6x | |
PEG Ratio | −0.26 | 0.01 | 0.00 | |
Price/Book | 7.8x | 2.1x | 2.6x | |
Price / LTM Sales | 6.0x | 2.0x | 3.1x | |
Upside (Analyst Target) | - | −2.0% | 53.6% | |
Fair Value Upside | Unlock | 1.9% | 8.0% | Unlock |